A familiar peptide name does not always identify one chemical entity. It may point to a sequence, modified molecule, salt, conjugate, metal complex, fragment, or mixture. Identity has to be resolved before evidence, status, or a structure image can be transferred.
The atlas records that chain under Identity and structure assets and keeps product authentication separate in Product quality, authenticity, and testing.
Common name leads to aliases, sequence and modifications, chemical form, database identifiers, and an asset with a source sidecar. Mixtures and ambiguous identities stop at no single depiction. GHK-Cu, TB-500, thymalin, and cerebrolysin retain their documented caveats.
Sequence sources
Biological sequences are checked first against authoritative records such as UniProt, NCBI Protein, or a primary sequence publication. Synthetic analogues require the modified residue order plus terminal changes, crosslinks, lipidation, glycosylation, pegylation, stereochemistry, or other defining chemistry.
A one-letter sequence alone may omit exactly the feature that distinguishes a medicine from an An entry with substantial scientific visibility or identity value. Biological rationale and non-human evidence do not establish patient benefit. Fuente de la definición: Scope and selection methodology · Glosario peptide. The identity record therefore keeps the displayed sequence, modification notes, and source together.
Form distinctions
| Identity issue | Why it matters | Existing example | Atlas treatment |
|---|---|---|---|
| Salt or conjugate | Counterions or attached groups can change the chemical entity and product record | Semaglutide has defining sequence modifications | Record the exact modified form; do not transfer an unmodified depiction |
| Metal complex | A peptide name and a database complex can have different stoichiometric scope | GHK-Cu | Retain the bis-complex caveat on the cited PubChem asset |
| Mixture | One name may cover many peptides without one sequence or molecular formula | Thymalin and cerebrolysin | Record the mixture boundary; omit a false single structure |
| Stereochemistry or modification | Residue order can look identical while three-dimensional chemistry differs | Modified clinical analogues | Record stereochemical and modification context with the sequence |
| Fragment ambiguity | A market label may refer to full-length protein or a shorter fragment | TB-500 | Preserve both documented meanings and avoid one universal depiction |
PubChem structures and their limits
PubChem is useful for stable identifiers, formulae, molecular weights, and standardized two-dimensional records. It is an evidence pointer, not proof that every material sold under a similar name has that identity.
A two-dimensional asset also omits conformational dynamics, formulation state, impurities, aggregation, counterion context, and sample provenance. For macromolecules or undefined mixtures, UniProt, ChEBI, a primary paper, or an explicit “no single depiction” record may be more accurate than a forced PubChem image.
Boundary cases with ambiguous identity
The atlas keeps unresolved boundaries visible:
GHK-Cu distinguishes free GHK from copper complexes and notes that the retained PubChem record represents a particular complex rather than every use of the name.
TB-500 records both the full-length thymosin beta-4 association and the shorter marketed fragment rather than treating them as interchangeable.
Thymalin and cerebrolysin are heterogeneous tissue-derived mixtures, so one sequence, formula, or structure would create false precision.
An unresolved identity is not filled by guesswork. The record states what is known, what remains ambiguous, and why a single asset is omitted.
Asset provenance
Every generated structure asset should carry a source sidecar recording the identifier, retrieval date, source URL, generation method, and caveat. That makes the image auditable and refreshable instead of decorative.
The provenance chain does not authenticate a physical sample. Authentication requires sample-specific analytical evidence and validated comparison standards; a database image cannot supply that evidence.
Refresh policy
Identity records and assets are refreshed when a source database changes, a better authoritative record appears, or the atlas resolves a previously ambiguous form. The last-verified date records when the source chain was checked, not a guarantee that no later correction exists.
Identity verification matters because every downstream statement depends on scope. A study of one sequence or pharmaceutical form does not automatically support a fragment, complex, mixture, or marketed material with a similar name.